Clinical trials: Obese Non Diabetic
Hypogonadism, Male, Diabetes Mellitus, Type 2
Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2)
Aim of the study was to investigate the effects of testosterone replacement therapy on components of metabolic syndrome, vascular function and morphology, grade of non-alcoholic fatty liver disease (NAFLD), bone mineral density…
- Conditions
- Hypogonadism, Male, Diabetes Mellitus, Type 2, Obesity
- Trial name
- SETH2 (NCT03792321)
- Testing
- Testosterone Undecanoate
- Volunteers
- 55 people
- Sponsor
- University Medical Centre Ljubljana
Overweight, Obese
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
The purpose of this study is to evaluate the multiple dose safety and tolerability of RM-493 (setmelanotide) as well as pharmacokinetic (PK) and pharmacodynamic (PD; weight loss) profile, in healthy obese patients for 2 to 4…
- Trial name
- NCT02431442
- Testing
- RM-493
- Volunteers
- 57 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Diabetes
Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects
To investigate whether the daily glucose profiles as assessed by continuous glucose monitoring for 1 week of normal weight and obese individuals relate to hunger levels and food intake.
- Trial name
- NCT02673203
- Testing
- Continuous Glucose Monitoring System (CGMS), Food log
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Pregnancy Complications, Obesity
Metformin in Obese Non-diabetic Pregnant Women
Obesity is on the rise in all developed countries. Of particular concern is that more young people including children are being recognised as being overweight or obese.
- Trial name
- MOP (NCT01273584)
- Testing
- Metformin
- Where
- 3 sites in United Kingdom
- Volunteers
- 450 people
- Sponsor
- Epsom and St Helier University Hospitals NHS Trust
Obesity
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
This is a Phase 1, randomized, blinded, placebo-controlled study in up to approximately 51 non-diabetic obese participants with a body mass index (BMI) ≥ 35 kg/m^2.
- Trial name
- NCT03625778
- Testing
- MEDI0382
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes, Obesity
Lifestyle Intervention in Obese Non-diabetic Adults With a Family History of Diabetes.
The aim of this study is to investigate weather gradual weight loss achieved with healthy lifestyle changes influence hormonal factors affecting appetite and blood glucose control in obese people without presence of diabetes.
- Trial name
- NCT00993603
- Testing
- 8-month group lifestyle programme
- Where
- United Kingdom
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- The Royal Bournemouth Hospital
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Inflammation
Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study
Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.
- Trial name
- NCT01161394
- Testing
- Pioglitazone 15mg, pioglitazone 30mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Type 2 Diabetes Mellitus
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
Primary Objectives: Main study: To assess in overweight to obese subjects and type 2 diabetes mellitus (T2DM) patients not requiring anti-diabetic pharmacotherapy the safety and tolerability of 3 different dose escalation…
- Trial name
- NCT03414736
- Testing
- SAR425899
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanofi
Non-Insulin-Dependent Diabetes Mellitus, Obesity
Efficacy and Safety of ATL-962 in Obese Diabetics
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
- Trial name
- NCT00156897
- Testing
- ATL-962, Orlistat
- Where
- 37 sites in Denmark, Finland and 3 more
- Volunteers
- 600 people
- Sponsor
- Alizyme
Obesity, Sarcopenia
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%.
- Trial name
- GLP1-SARCO (NCT07858864)
- Testing
- GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Istanbul Saglik Bilimleri University
Type 2 Diabetes
Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar
The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM.
- Trial name
- NCT04081064
- Testing
- 10-week exercise programme based on aerobic interval and resistance training
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Adenocarcinoma of the Endometrium
A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
The purpose of this research is to determine the effects of Metformin, a well tolerated drug widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.
- Trial name
- NCT01877564
- Testing
- Metformin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Obesity, Dapagliflozin Adverse Reaction
The Effect of Dapagliflozin on Weight Loss in Obese Adults Without Diabetes
The goal of this clinical trial is to examine the effectiveness of a drug named dapagliflozin (tested drug) on weight loss in young adults aged between 18 and 40 years with obesity who are not diagnosed with diabetes.
- Conditions
- Obesity, Dapagliflozin Adverse Reaction, Weight Loss, Effect of Drug
- Trial name
- DAPA-ANDO (NCT06000462)
- Testing
- Dapagliflozin 10mg Tab, Metformin 1000 mg (ttd)
- Where
- Oman
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Oman Ministry of Health
Kisspeptin Action on Insulin in Healthy Normal Men, Kisspeptin Action on Insulin in Obese Diabetic Men
KP-10 and Insulin Secretion in Men
Induction of insulin secretion by kisspeptin is observed in mouse, pig, rat, and human islets in vitro and in rats, mice and monkeys in vivo, but its mechanism is not fully clear.
- Trial name
- NCT03771326
- Testing
- Kisspeptin-10
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Quaid-e-Azam University
Overweight , Obesity
Phase 3 Study of MWN109 Injection in Participants With Overweight or Obesity
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of MWN109 injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07778693
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 760 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Insulin Resistance
Insulin Resistance and Severity of Coronary Artery Disease
this is an observertional study aimed at Study the association between Insulin resistance estimated by HOMA and Angiographic Severity of Coronary Artery Disease in Non Diabetic \& Non Obese Patients.
- Trial name
- NCT05215821
- Where
- Egypt
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Sohag University
Type II Diabetes Mellitus, Obesity
A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics
One out of two adults in Canada is currently overweight and therefore at increased risk for a number of medical conditions including diabetes, high blood pressure, heart attacks and stroke.
- Trial name
- NCT01644201
- Testing
- PolyGlycopleX® - PGX®
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- InovoBiologic Inc.
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Overweight , Obesity
Phase Ib Clinical Study of MWN109 Injection in Participants With Overweight or Obesity
This study is a randomized, double-blind, placebo-controlled, multiple-dose phase Ib clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity characteristics of MWN109…
- Trial name
- NCT07787728
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd